BRIEF published on 12/09/2025 at 14:55, 8 months 2 days ago Teva Pharmaceuticals submits an application for authorization for Olanzapine LAI FDA Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 8 months 2 days ago Medincell and Teva Submit FDA Application for New Injectable Treatment Schizophrenia Treatment Medincell FDA Submission Teva Pharmaceuticals Olanzapine LAI
PRESS RELEASE published on 12/09/2025 at 14:50, 8 months 2 days ago Inside Information / Other news releases Teva Pharmaceuticals submits NDA to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for Once-Monthly Schizophrenia Treatment. Medincell focuses on long-acting injectable treatments across therapeutic areas Schizophrenia Medincell Olanzapine NDA Teva Pharmaceuticals
BRIEF published on 11/11/2025 at 08:05, 9 months ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
PRESS RELEASE published on 11/11/2025 at 08:00, 9 months ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 9 months 6 days ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 9 months 6 days ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
BRIEF published on 10/10/2025 at 22:16, 10 months 1 day ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
PRESS RELEASE published on 10/10/2025 at 22:11, 10 months 1 day ago Inside Information / Other news releases FDA approves UZEDY as extended-release injectable suspension for bipolar I disorder treatment in adults. Teva and Medincell collaborate on this significant advancement in neuroscience FDA Medincell Teva UZEDY Bipolar I Disorder
BRIEF published on 09/17/2025 at 14:05, 10 months 24 days ago Medincell and Teva Present Phase 3 Olanzapine LAI Data Phase 3 Trial Schizophrenia Treatment Medincell Teva Olanzapine LAI
Published on 08/12/2026 at 00:00, 7 hours 53 minutes ago Organto Foods Reports Record Second Quarter 2026 Financial Results
Published on 08/11/2026 at 23:40, 8 hours 13 minutes ago RJK Explorations Ltd. Announces Private Placement for Gross Proceeds of up to $100,000
Published on 08/11/2026 at 23:15, 8 hours 38 minutes ago Fermi and Hillcore Energy Capital Announce 2.6 Gigawatt Power Strategic Alliance for Project Matador
Published on 08/11/2026 at 23:00, 8 hours 53 minutes ago Prospectiva Resources Ltd. Completes Qualifying Transaction
Published on 08/11/2026 at 22:55, 8 hours 58 minutes ago NV Gold Announces Non-Brokered Private Placement
Published on 08/12/2026 at 07:45, 8 minutes ago Delignit AG reports significant increase in revenue and earnings in the first half of 2026 and confirms its guidance
Published on 08/12/2026 at 07:30, 23 minutes ago BIKE24 continues growth trajectory in the second quarter of 2026 and strengthens its position in the European market
Published on 08/12/2026 at 07:30, 23 minutes ago wienerberger strengthens its position in infrastructure and renovation – Q2 2026 results
Published on 08/12/2026 at 07:30, 23 minutes ago Sensirion’s SGM5304 gas meter module successfully achieves EN 17526 certificatio
Published on 08/12/2026 at 07:30, 23 minutes ago GESCO recorded a solid performance in the first half of 2026 despite persistently challenging conditions
Published on 08/10/2026 at 18:00, 1 day 13 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 11:53, 1 day 19 hours ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:36, 1 day 20 hours ago GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
Published on 08/10/2026 at 09:22, 1 day 22 hours ago Number of shares and voting rights - July 2026 (In French only)
